Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Sun Drug: Sales, Profits Show Double-Digit Increases
May 28, 2001
- SSP, Nihon Tenganyaku to Jointly Research Antifungal Eye Drop
May 21, 2001
- \240,000 Necessary per Month forNursing Care: Survey Respondents
May 21, 2001
- Kissei Completes Therapeutic Nutritive Food Business Center
May 21, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2001
- Ethical Drugs Achieve 2.5% Growth in FY2000
May 21, 2001
- WORLD NEWS ON BRIEF
May 21, 2001
- Sankyo Stresses Fewer Drug Interactions for Mevalotin
May 21, 2001
- Sanofi-Synthelabo, Organon to Jointly Start PII for Pentasaccharide
May 21, 2001
- Daiichi Applies for Chronic Heart Failure as New Indication for Carvedilol
May 21, 2001
- Nippon BD to Open Lab in Advanced Medical Center in Kobe
May 21, 2001
- Dainippon Licenses Antipsychotic Blonanserin to Almirall
May 21, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 21, 2001
- BUSINESS NEWS IN BRIEF -1-
May 21, 2001
- PAJ New Chairman to Be Enthusiastic about Promoting Self-medication
May 21, 2001
- BUSINESS NEWS IN BRIEF -2-
May 21, 2001
- Kawachi Yakuhin Ties Up with Sun Drug
May 21, 2001
- Rituximab Recommended for Approval: CDFS
May 21, 2001
- Korosho Issues Notifications of Revision of Specifications and Test Method Guidelines
May 21, 2001
- Average Household's Healthcare Spending Down in FY2000
May 21, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…